Allegro was founded in 2021 with the aim to improve the quality of life of patients with chronic degenerative diseases through novel biomedical nanotechnology.
Who are we?
Allegro is a new breed of life sciences company, designing, developing and commercializing break-through products at the intersection of biotech, nanotech and medtech. We specialize in cutting edge biomedical nanotechnology for the qualitative extension of life.
Our family of world-class colleagues have but one ambition, which is to progress humankind, with our passion, relentlessness and love.
Allegro Biotech’s team of eleven, boasting seven PhD holders, embodies excellence in biotechnology. Their combined expertise fuels innovation, propelling the company to the forefront of groundbreaking research and development. With a commitment to pushing boundaries, they are driving transformative advancements in the field of biotechnology.
Jorg Schelfhout and Lucas Decuypere embarked on the journey of founding Allegro driven by an unwavering passion for lifesciences and a profound commitment to alleviating the burden of chronic degenerative diseases on patients worldwide. Supported by a world-class board, their vision is not just to innovate but to redefine treatment in osteoarthritis.
Meet the management team and the board here.
Allegro’s cutting-edge laboratories and pilot production facilities at Légiapark, Liège, Belgium, are at the forefront of biomedical nanotechnology. Equipped with state-of-the-art technology, they enable Allegro to excel in research and development, driving innovation and advancing life sciences.